Neutropenia after single-dose clindamycin for dental prophylaxis

Pharmacotherapy

Volumn 23, Issue 1, 2003, Pages 101-103

  Bubalo, Joseph S ^a   Blasdel, Carolyn S ^a   Bearden, David T ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN;

AGED; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; HUMAN; MALE; NEUTROPENIA; NEUTROPHIL; PREVENTIVE DENTISTRY; TOOTH EXTRACTION;

EID: 0037224682     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.1.101.31920     Document Type: Article

References (11)

1. Steigbigel NH. Macrolides and clindamycin. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000:366-82.
2. Pharmacia and Upjohn. Cleocin (clindamycin hydrochloride) package insert. Kalamazoo, MI; November 1998.
3. Fleming GE Crowe GR. Granulocytopenia due to clindamycin [letter]. Med J Aust 1976 Jan 17;1(3):70.
4. Sen P, Tecson F, Kapila R, Louria DB. Clindamycin in the oral treatment of putative anaerobic pneumonias. Arch Intern Med 1974; 134(July):73-7.
5. Fulghum DD, Catalano PM. Stevens-Johnson syndrome from clindamycin. JAMA 1973;223:318-19.
6. Pickering LK, Feigin RD. Stevens-Johnson syndrome [letter]. JAMA 1973;223:1392.
7. Pisciotta AV. Agranulocytosis during antibiotic therapy: drug sensitivity or sepsis? Am J Hematol 1993;42:132-7.
8. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
9. Uetrecht JP. Reactive metabolites and agranulocytosis. Eur J Haematol Suppl 1996;60:83-8.
10. Druker BJ. STI571: a paradigm for clinical trials of molecularly targeted agents. In: Education book from the 37th annual meeting of the American Society of Clinical Oncology. Alexandria, VA: American Society of Clinical Oncology, 2001:419-25.
11. Shawver LK. Tyrosine kinase inhibitors: from the emergence of targets to their clinical development. In: Education book from the 35th annual meeting of the American Society of Clinical Oncology, Alexandria, VA: American Society of Clinical Oncology, 1999:29-47.